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obituary

Ion Gresser 1928–2019

I

on Gresser, a virologist who transformed
understanding of the roles of interferons,
may be best remembered for showing
that in mice, interferon-α (IFN-α) can
produce acute and chronic disease. At the
time Gresser began these studies, interferon
was considered to be a selective antiviral
substance, harmless to uninfected cells and
organisms, and there was no indication that
cytokines would play a role in pathogenesis.
That belief was shattered with the 1975
Nature publication with the simple title
“Lethality of interferon preparations for
newborn mice.”
Gresser subsequently demonstrated
that antibodies to IFN-α can protect young
mice from death caused by infection with
lymphocytic choriomeningitis virus. This
study can be considered a stepping-stone
for the therapeutic application of antibodies
to cytokines in the treatment of human
disease, which was introduced much later
and revolutionized the management of some
autoimmune diseases.
Since its first description by Alick Isaacs
and Jean Lindenmann in 1957, interferon
was believed to be important in an
organism’s resistance to viral infection and
was thought to have the potential to become
as useful in the treatment of viral diseases as
penicillin and other antibiotics had turned
out to be for infections caused by bacteria.
Gresser made substantial contributions to
the body of knowledge about interferon
that is now taken for granted. His early
studies of mouse models of viral infections
established that injections of IFN-α can
indeed protect mice from viral infection.
Gresser was among the first investigators to
explore the potential of interferons in the
control of malignancies in animal models,
showing that it can protect mice not only
from leukemias caused by viruses but also
from solid tumors and metastatic cancer.
Those findings contributed to the original
optimism about the potential usefulness
of interferons not only in the treatment of
viral infections but also in the control of
cancer in humans. Unfortunately, those
expectations were generally not borne out
by later clinical trials. Although interferon
therapies would show moderate efficacy in
the control of some viral infections, such as
chronic active infection with hepatitis virus
B or C, and even more modest results in
some malignancies, the benefits fell short of
the initial expectations.

More surprising at the time was the first
demonstration, by Gresser and colleagues
in 1973, that IFN-α enhances the expression
of histocompatibility antigens and modifies
the surface of uninfected cells, and that
it has other immunomodulatory actions.
Those last findings were among the first
demonstrations that interferons have actions
separate from their antiviral activities and
broadened the scope of interferon research.
A native of New York City, Gresser
developed early on an appreciation of
science and the arts. His mother, Gisela
Kahn Gresser, was a classicist and
prominent chess player who dominated
women’s chess for more than three decades,
winning nine national titles between 1944
and 1969. His father, William Gresser,
a successful attorney, moonlighted as a
serious musicologist. Ion Gresser — who
too retained a life-long passion for the
piano and classical music — completed his
undergraduate studies at Harvard University.
In addition to science, he was interested in
history, European literature and Russian.
After his graduation from Yale School
of Medicine and an internship at Bellevue
Hospital in New York City, he joined the
army and served as head of an infectious
disease laboratory at the army post in Camp
Zama, Japan. There he developed an active
interest in virology and published his first
papers on Japanese encephalitis and Asian
flu — a passion that blossomed during a
postdoctoral fellowship in the laboratory of
John F. Enders, the Harvard-based virologist
and co-recipient of the 1954 Nobel Prize in
physiology or medicine. While working in
Enders’ lab, Gresser also published his first
paper devoted to interferons.
A Francophile, Gresser moved to Paris in
the early 1960s, first joining the laboratory
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of another interferon pathfinder, Charles
Chany, at the Hôpital St. Vincent de Paul,
and soon thereafter establishing his own
laboratory at the Institut de Recherches
Scientifiques sur le Cancer in Villejuif,
outside Paris. Eventually, Gresser ended up
spending decades at the Villejuif laboratory,
and it was there that he conducted all of
his many original studies for which he
became known. Although he retired from
his position at Villejuif many years ago,
he continued to publish reviews, as well
as original research in collaboration with
others. His very last paper, co-authored with
Pierre Lebon, Yanick Crow and Jean-Laurent
Casanova, appeared in March of this year,
only weeks before his passing.
Arguably, the most important
contribution of Gresser and his colleagues
was the demonstration of harmful effects
of interferons in animal models, as well
as the clear evidence that interferons
contribute to pathogenesis, including the
pathogenesis of viral infections. Among
the most surprising discoveries was
that injection of mice with potent sheep
immunoglobulin directed against IFN-α
markedly inhibits the manifestations
of disease caused by infection with
lymphocytic choriomeningitis virus
(weight loss, liver-cell necrosis and death),
despite the fact that the treated mice had
100-fold more of the virus in their serum
than did mice that were not treated with
the anti-interferon immunoglobulin. At
the time of their publication in 1977,
these findings not only were completely
unexpected and counterintuitive but
also presaged the advent of the dramatic
beneficial effects of anti-cytokine therapies
in humans, such as those achieved with
the use of monoclonal antibodies to the
cytokine TNF in the treatment rheumatoid
arthritis, Crohn’s disease and some other
autoimmune disorders. This discovery
alone would be sufficient to earn Ion
Gresser a lasting abode in the pantheon
of medical science.
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